Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Osteoporos Int. 2008; 19: 733-759
- Adverse effects of bisphosphonates: implications for osteoporosis management.Mayo Clin Proc. 2009; 84 ([quiz: 638]): 632-637
- Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.Bone. 2006; 38: 617-627
- To stop or not to stop, that is the question.Osteoporos Int. 2009; 20: 187-195
- Long-term use of bisphosphonates in osteoporosis.J Clin Endocrinol Metab. 2010; 95: 1555-1565
- Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.J Bone Miner Res. 2010; 25: 2251-2255
- Ten years’ experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med. 2004; 350: 1189-1199
- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA. 2006; 296: 2927-2938
- Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.Am J Med. 1997; 103: 291-297
- Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.J Bone Miner Res. 1994; 9: 1833-1837
- Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.Ann Intern Med. 2002; 137: 875-883
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.Bone. 2008; 43: 222-229
- Fracture risk remains reduced one year after discontinuation of risedronate.Osteoporos Int. 2008; 19: 365-372
- The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial.J Bone Miner Res. 2010; 25 ([abstract:1070]): S22
- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.N Engl J Med. 1995; 333: 1437-1443
- Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group.J Clin Endocrinol Metab. 2000; 85: 3109-3115
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.JAMA. 1999; 282: 1344-1352
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med. 2007; 356: 1809-1822
- Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.Osteoporos Int. 2009; 20: 943-948
- The effect of 3 versus 6 years of zolendronic acid treatment in osteoporosis: a randomized extension in the HORIZON-pivotal fracture trial (PFT).J Bone Miner Res. 2010;
- Bone mass after withdrawal of oestrogen replacement.Lancet. 1981; 1: 1053-1054
- Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy.Lancet. 1981; 1: 459-461
- Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.Bone. 2002; 30: 599-603
- The waning effect of postmenopausal estrogen therapy on osteoporosis.N Engl J Med. 1993; 329: 1192-1193
- The effect of postmenopausal estrogen therapy on bone density in elderly women.N Engl J Med. 1993; 329: 1141-1146
- Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women.Osteoporos Int. 2001; 12: 385-390
- The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.Bone. 2010; 46: 592-597
- Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.J Clin Endocrinol Metab. 2011; 96: 972-980
- Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.J Bone Miner Res. 2005; 20: 1507-1513
- Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.Arch Intern Med. 2004; 164: 2024-2030
- Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.Osteoporos Int. 2005; 16: 510-516
- Fracture outcomes related to persistence and compliance with oral bisphosphonates.J Bone Miner Res. 2008; 23: 1569-1575
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Osteoporos Int. 2008; 19: 1613-1620
- Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.JAMA. 2011; 305: 783-789
- Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.J Bone Miner Res. 2010; 25: 976-982
- Role of hormone therapy in the management of menopause.Obstet Gynecol. 2010; 115: 839-855
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Changes in bone density and turnover after alendronate or estrogen withdrawal.Menopause. 2004; 11: 622-630
- Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.Arch Intern Med. 2003; 163: 789-794
- Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment.Obstet Gynecol. 2004; 103: 440-446
- Safety assessment of raloxifene over eight years in a clinical trial setting.Curr Med Res Opin. 2005; 21: 1441-1452
- Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.Menopause. 2008; 15: 790-796
- How long should patients take medications for postmenopausal osteoporosis?.Joint Bone Spine. 2007; 74: 24-31
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009; 361: 756-765
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.J Clin Endocrinol Metab. 2011; 96: 394-402
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.N Engl J Med. 2001; 344: 1434-1441
- Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.Arthritis Rheum. 2009; 60: 3346-3355
- Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.Acta Orthop. 2009; 80: 413-415
Dell R, Greene D, Ott S, et al. A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. ASBMR Annual Meeting. Toronto, Canada, 2010. p. S61 [abstract: 1201].
- Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res. 2010; 25: 2267-2294
- Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.N Engl J Med. 2010; 362: 1761-1771
- Bisphosphonate use and atypical fractures of the femoral shaft.N Engl J Med. 2011; 364: 1728-1737
- Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007.J Bone Miner Res. 2011; 26: 553-560
- Numeracy skill and the communication, comprehension, and use of risk-benefit information.Health Aff (Millwood). 2007; 26: 741-748
- What’s more dangerous, your aspirin or your car? Thinking rationally about drug risks (and benefits).Health Aff (Millwood). 2007; 26: 636-646
- Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.J Bone Miner Res. 2009; 24: 1998-2006
- Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.Osteoporos Int. 2010; 21: 2027-2036
- Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.J Bone Miner Res. 2010; 25: 2297-2303
- A before-and-after study of fracture risk reporting and osteoporosis treatment initiation.Ann Intern Med. 2010; 153: 580-586
- Simplifying screening for osteoporosis in Australian primary care: the Prospective Screening for Osteoporosis; Australian Primary Care Evaluation of Clinical Tests (PROSPECT) study.Menopause. 2011; 18: 53-59
- Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?.Best Pract Res Clin Rheumatol. 2005; 19: 975-981
Article info
Footnotes
Financial Disclosure/Conflict of Interest: A.J.L.: Consulting/Speakers Bureau: Amgen, Genentech, Lilly, Novartis, Roche GSK. S.B.T.: Consulting/Honoraria/Research Support: Amgen, Pfizer, Lilly, Merck, Novartis, Genentech, Roche, UCB, Centocor, AstraZeneca, BMS.
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
